1167 related articles for article (PubMed ID: 23209033)
1. The definition of primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033
[TBL] [Abstract][Full Text] [Related]
2. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
4. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
[TBL] [Abstract][Full Text] [Related]
5. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
6. Genetic pathways to primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
[TBL] [Abstract][Full Text] [Related]
7. MET gain in diffuse astrocytomas is associated with poorer outcome.
Pierscianek D; Kim YH; Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Wrede K; Nakazato Y; Tanaka Y; Mariani L; Vital A; Sure U; Ohgaki H
Brain Pathol; 2013 Jan; 23(1):13-8. PubMed ID: 22672415
[TBL] [Abstract][Full Text] [Related]
8. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
Ichimura K; Pearson DM; Kocialkowski S; Bäcklund LM; Chan R; Jones DT; Collins VP
Neuro Oncol; 2009 Aug; 11(4):341-7. PubMed ID: 19435942
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Watanabe T; Nobusawa S; Kleihues P; Ohgaki H
Am J Pathol; 2009 Apr; 174(4):1149-53. PubMed ID: 19246647
[TBL] [Abstract][Full Text] [Related]
10. Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma.
Hata N; Suzuki SO; Murata H; Hatae R; Akagi Y; Sangatsuda Y; Amano T; Yoshimoto K; Tahira T; Mizoguchi M
Pathol Oncol Res; 2015 Jul; 21(3):839-43. PubMed ID: 25354913
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
[TBL] [Abstract][Full Text] [Related]
12. Genetic profile of astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
Brain Tumor Pathol; 2011 Jul; 28(3):177-83. PubMed ID: 21442241
[TBL] [Abstract][Full Text] [Related]
13. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
14. Phenotype vs genotype in the evolution of astrocytic brain tumors.
Kleihues P; Ohgaki H
Toxicol Pathol; 2000; 28(1):164-70. PubMed ID: 10669004
[TBL] [Abstract][Full Text] [Related]
15. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
[TBL] [Abstract][Full Text] [Related]
16. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T
Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261
[TBL] [Abstract][Full Text] [Related]
17. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
19. PDGFRA gain in low-grade diffuse gliomas.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Nonoguchi N; Pierscianek D; Kim YH; Mariani L; Vital A; Perry A; Ohgaki H
J Neuropathol Exp Neurol; 2013 Jan; 72(1):61-6. PubMed ID: 23242283
[TBL] [Abstract][Full Text] [Related]
20. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]